Opiant Pharmaceuticals, Inc. (OPNT) Research

Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.

Market snapshot

Symbol
OPNT
Price
$20.65
Day change
0.00%
Market cap
$108.8M
P/E ratio
30.58x
52-week range
7.34-27.36
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Aadi Bioscience, Inc. (AADI)
  • Cyteir Therapeutics, Inc. (CYT)
  • Decibel Therapeutics, Inc. (DBTX)
  • Graybug Vision, Inc. (GRAY)
  • HilleVax, Inc. (HLVX)
  • Jounce Therapeutics, Inc. (JNCE)
  • Miromatrix Medical Inc. (MIRO)
  • Paratek Pharmaceuticals, Inc. (PRTK)

Recent insider activity

  • Silver Gabrielle Alison — D-Return (21343 shares) on 2023-03-02
  • Silver Gabrielle Alison — D-Return (2500 shares) on 2023-03-02
  • Silver Gabrielle Alison — D-Return (2500 shares) on 2023-03-02
  • Silver Gabrielle Alison — D-Return (2500 shares) on 2023-03-02
  • Silver Gabrielle Alison — D-Return (2000 shares) on 2023-03-02

Open Opiant Pharmaceuticals, Inc. (OPNT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.